With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
The current price of Novo Nordisk A/S in the market is ₺2.009,87, with a 24-hour trading volume of ₺182,83M. The asset's market cap is ₺8,9T, after moving -1.02% in the last day.
Tokenized Novo Nordisk A/S is trading at ₺2.047,6, with a tokenized market cap of ₺163,89M and a 24-hour trading volume of ₺47,19M. The tokenized asset has moved -2.26% in the past 24 hours.